These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25168691)

  • 1. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis.
    Yamasaki Y; Nouso K; Miyahara K; Wada N; Dohi C; Morimoto Y; Kinugasa H; Takeuchi Y; Yasunaka T; Kuwaki K; Onishi H; Ikeda F; Miyake Y; Nakamura S; Shiraha H; Takaki A; Iwasaki Y; Amano M; Nishimura S; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):528-34. PubMed ID: 25168691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis.
    Blomme B; Francque S; Trépo E; Libbrecht L; Vanderschaeghe D; Verrijken A; Pattyn P; Nieuwenhove YV; Putte DV; Geerts A; Colle I; Delanghe J; Moreno C; Gaal LV; Callewaert N; Vlierberghe HV
    Dig Liver Dis; 2012 Apr; 44(4):315-22. PubMed ID: 22119618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis.
    Chen C; Schmilovitz-Weiss H; Liu XE; Pappo O; Halpern M; Sulkes J; Braun M; Cohen M; Barak N; Tur-Kaspa R; Vanhooren V; Van Vlierberghe H; Libert C; Contreras R; Ben-Ari Z
    J Proteome Res; 2009 Feb; 8(2):463-70. PubMed ID: 19140676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum protein N-glycosylation in paediatric non-alcoholic fatty liver disease.
    Blomme B; Fitzpatrick E; Quaglia A; De Bruyne R; Dhawan A; Van Vlierberghe H
    Pediatr Obes; 2012 Apr; 7(2):165-73. PubMed ID: 22434757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Differential Diagnosis of Liver Iron Contents in Nonalcoholic Steatohepatitis and Simple Steatosis Using Multiecho Dixon Magnetic Resonance Imaging.
    Kim TH; Jeong CW; Jun HY; Kim YR; Kim JY; Lee YH; Yoon KH
    Acad Radiol; 2019 Jun; 26(6):766-774. PubMed ID: 30143402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.
    Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E
    Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.
    Kamada Y; Fujii H; Fujii H; Sawai Y; Doi Y; Uozumi N; Mizutani K; Akita M; Sato M; Kida S; Kinoshita N; Maruyama N; Yakushijin T; Miyazaki M; Ezaki H; Hiramatsu N; Yoshida Y; Kiso S; Imai Y; Kawada N; Takehara T; Miyoshi E
    Proteomics Clin Appl; 2013 Oct; 7(9-10):648-56. PubMed ID: 23775887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
    Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study.
    Bastati N; Feier D; Wibmer A; Traussnigg S; Balassy C; Tamandl D; Einspieler H; Wrba F; Trauner M; Herold C; Ba-Ssalamah A
    Radiology; 2014 Jun; 271(3):739-47. PubMed ID: 24576046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
    Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
    Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis.
    Ogawa K; Kobayashi T; Furukawa JI; Hanamatsu H; Nakamura A; Suzuki K; Kawagishi N; Ohara M; Umemura M; Nakai M; Sho T; Suda G; Morikawa K; Baba M; Furuya K; Terashita K; Kobayashi T; Onodera M; Horimoto T; Shinada K; Tsunematsu S; Tsunematsu I; Meguro T; Mitsuhashi T; Hato M; Higashino K; Shinohara Y; Sakamoto N
    Sci Rep; 2020 Jan; 10(1):321. PubMed ID: 31941930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
    Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population.
    Hasegawa Y; Kim SR; Hatae T; Ohta M; Fujinami A; Sugimoto K; Kim KI; Imoto S; Tohyama M; Kim SK; Ikura Y; Kudo M
    Dig Dis; 2015 Oct; 33(6):715-20. PubMed ID: 26488474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.